Michael Pehl

Chief Executive Officer at

ADCendo ApS

62 year

Health Technology

Consumer Services

Profile

Michael Pehl is Chief Executive Officer & Director at ADCendo ApS since 2021.
Formerly, Mr. Pehl was President, Chief Executive Officer & Director at Immunomedics, Inc. from 2017 to 2019, Chief Executive Officer at AvenCell Europe GmbH, and President-Global Hematology/Oncology at Celgene Corp.
from 2006 to 2017.
Mr. Pehl completed undergraduate education at Ludwig-Maximilians-Universität München.

Michael Pehl active positions

Companies	Position	Start
ADCendo ApS ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers	Chief Executive Officer	07/07/2021

All active positions of Michael Pehl

Former positions of Michael Pehl

Companies	Position	End
IMMUNOMEDICS, INC.	Chief Executive Officer	23/02/2019
CELGENE	Corporate Officer/Principal	21/08/2017
GEMoaB Monoclonals GmbH GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products	Chief Executive Officer	-

See the detail of Michael Pehl's experience

Training of Michael Pehl

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Pehl's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Celgene Corp. Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs	Health Technology
Immunomedics, Inc. Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer	Health Technology
Ludwig-Maximilians-Universität München Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
ADCendo ApS ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers	Health Technology
GEMoaB Monoclonals GmbH GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products	Health Technology